This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Snyderwine, E. G. Articles by Thorgeirsson, S. S. Search for Related Content PubMed PubMed Citation Articles by Snyderwine, E. G. Articles by Thorgeirsson, S. S.

Metabolic Activation and Genotoxicity of Heterocyclic Arylamines¹

Laboratory of Experimental Carcinogenesis [E. G. S., S. S. T.] and Office of the Director [R. H. A., U. P. T.], Division of Cancer Etiology, National Cancer Institute, Bethesda, Maryland 20892, and Department of Pathology, Medical College of Ohio, Toledo, Ohio 43614 [H. A. J. S.]

Because of the potential for human exposure to mutagenic and carcinogenic heterocyclic arylamines in the diet, the carcinogenicity of three HAAs, 2-amino-3-methylimidazo[4,5-f]quinoline, 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline, and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine, is being evaluated in nonhuman primates, especially cynomolgus monkeys. Concomitant with the carcinogenicity studies, the metabolic processing, disposition, and DNA-adduct formation of these compounds are being examined in these monkeys. This report highlights the results from studies in monkeys and from in vitro models examining metabolic activation and genotoxicity of HAAs. The extent of in vivo activation of HAAs in monkeys was assessed by measuring DNA adducts in various tissues. Both 2-amino-3-methylimidazo[4,5-f]quinoline and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine form high levels of DNA adducts in a number of organs, particularly the liver, kidney, and heart. The implications of metabolic activation and DNA-adduct formation to the carcinogenicity of HAAs are discussed.